Entry of Bill Gates and additional investment from existing syndicate raises Series B total to $87 million NEW YORK, December 5, 2018-- Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of its previously announced Series B financing, bringing the Series B round total to $87 million. The company will use the additional funds to further advance its portfolio of programs targeting the gut-brain axis. Kallyope has now raised $131 million in equity capital since inception. The expanded financing was led by Bill Gates.